• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>RSC Advances >Surface-active drug loaded lipopolymeric nanohybrid aerosol therapy: potential non-invasive way to mitigate lipopolysaccharide mediated inflammation in murine lungs
【24h】

Surface-active drug loaded lipopolymeric nanohybrid aerosol therapy: potential non-invasive way to mitigate lipopolysaccharide mediated inflammation in murine lungs

机译：表面活性药物载荷脂质聚合物纳米嗜含量气溶胶治疗：潜在的非侵入性方式减轻尿嘧啶肺的脂多糖介导的炎症

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In the present study, surface-active lipopolymeric nanohybrids (LPH) measuring 200-300 nm were developed and evaluated for their efficacy as non-invasive aerosol therapy to reduce lung inflammation and lung injury in rats caused by 5 mg per kg body weight intratracheally administered lipopolysaccharide (LPS). The nanoparticles comprised of phospholipids DPPC and POPG along with polymeric anti-oxidant D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) or dexamethasone disodium phosphate (DXP) or both. The formulation closely mimics surface tension modulation properties like innate pulmonary surfactant (PS). The dual drug LPH (Dual-LPH) aerosol therapy provided maximum beneficial effect compared to individual drug loaded nanoparticle aerosol treatment. Chest X-rays and lung tissue histopathological studies revealed that Dual-LPH aerosol therapy at a dose of 200 mg phospholipid + 50 mg TPGS + 2 mg DXP per kg body weight significantly reduced inflammation, damage to the alveolar network and pulmonary hemorrhage in LPS injured rats. Significant reduction in levels of neutrophils, total protein, oxidative stress and inflammatory cytokines like TNF-alpha, IL-1 beta and IL-6 in bronchoalveolar lavage fluid (BALF) was seen in the Dual-LPH treated group. BALF capillary patency studies revealed rise in capillary patency from 0% for LPS injured group to 99.7 +/- 0.1% for Dual-LPH treated group, which is comparable to that of innate surfactant in healthy conditions, indicating that Dual-LPH treatment helped in opening occluded airways. Surface-active TPGS helped in scavenging the free radicals in the injured lungs whereas DXP helped in modulating the inflammation pathway. This multipronged approach can thus serve as a potential non-invasive treatment modality for reducing lung inflammation in lung injury cases.
机译：在本研究中，开发了表面活性的脂质聚合物纳米嗜含量（LPH）200-300nm的效果，以减少大鼠肺炎和肺损伤，以减少每公斤体重的大鼠肿瘤内施用5毫克脂多糖（LPS）。由磷脂DPPC和POPG组成的纳米颗粒以及聚合物抗氧化剂D-α-生育酰基聚乙二醇1000琥珀酸钠（TPG）或磷酸二钠（DXP）或两者。该配方非常模仿表面张力调制性质，如先天肺表面活性剂（PS）。与个体药物负载的纳米粒子气溶胶处理相比，双重药物溶解（双液体LPH）气溶胶疗法提供了最大的有益效果。胸部X射线和肺组织组织病理学研究表明，双洛氏气溶胶治疗剂量为200毫克磷脂+ 50mg TPGs + 2mg DXP每千克体重显着降低炎症，肺泡网络损伤和LPS肺出血受伤老鼠。在双洛克治疗组中，观察到中性粒细胞，总蛋白质，氧化应激和炎症细胞因子等嗜中性粒细胞，总蛋白质，氧化应激和炎症细胞因子等炎症性细胞因子的显着降低。 BALF毛细血管通畅研究显示，LPS受损组的0％透露毛细管通畅从0％上升至99.7 +/- 0.1％的双洛克治疗组，其与健康条件的先天表面活性剂相当，表明双洛克治疗有助于打开闭塞式航空公司。表面活性TPG有助于清除受伤肺中的自由基，而DXP有助于调节炎症途径。因此，这种多强的方法可以作为降低肺损伤病例中的肺炎的潜在的非侵入性治疗方式。

著录项

  • 来源
    《RSC Advances》 |2015年第13期|共12页
  • 作者

    Shah Apurva R.; Hagawane Tejashree; Kshirsagar Nilima; Banerjee Rinti;

  • 作者单位

    Indian Inst Technol Dept Biosci &

    Bioengn Bombay 400076 Maharashtra India;

    Maharashtra Univ Hlth Sci Dept Infect Dis Mumbai Maharashtra India;

    Indian Council Med Res Nat Chair Clin Pharmacol New Delhi India;

    Indian Inst Technol Dept Biosci &

    Bioengn Bombay 400076 Maharashtra India;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 化学;
  • 关键词

相似文献

  • 外文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号